Document:

EX-10.1

 Exhibit 10.1 

DATED JANUARY 14, 2015 

PRESBIA HOLDINGS 
 and

 PRESBIA PLC 
  

 
 SHARE
EXCHANGE DEED 
 for the acquisition of share capital of 

PRESBIA IRELAND, LIMITED 
  

 
 ARTHUR COX

 DUBLIN 

  

 TABLE OF CONTENTS 

 

							
	1	 	INTERPRETATION	  	 	2	  
	2	 	AGREEMENT OF THE BUYER TO ISSUE CONSIDERATION SHARES TO THE SELLER	  	 	3	  
	3	 	CONSIDERATION	  	 	3	  
	4	 	COMPLETION	  	 	3	  
	5	 	WARRANTIES	  	 	3	  
	6	 	POWER OF ATTORNEY	  	 	4	  
	7	 	ASSIGNMENT	  	 	4	  
	8	 	VARIATION	  	 	4	  
	9	 	WAIVER	  	 	4	  
	10	 	EFFECT OF COMPLETION	  	 	4	  
	11	 	COUNTERPARTS	  	 	5	  
	12	 	PROPER LAW AND SUBMISSION TO JURISDICTION	  	 	5	  
	SCHEDULE 1	  	 	6	  

  

 THIS DEED is made on January 14, 2015 between the following parties: 

 

	(1)	PRESBIA HOLDINGS, a Cayman Islands company (Registration No.: 188040) having its registered office at Stuarts Corporate Services Ltd., P.O. Box 2510, George Town, Grand Cayman KY1-1104, Cayman Islands (the
“Seller”); and 

  

	(2)	PRESBIA PLC, a public limited company incorporated in Ireland with registered number 539137 whose registered office is at Arthur Cox Building, Earlsfort Centre, Earlsfort Terrace, Dublin 2 (the
“Buyer”). 

 BACKGROUND 
  

	(A)	Presbia Ireland, Limited (the “Company”), details of which are set out in Schedule 1, was incorporated in Ireland with registered number 532722 and is a private limited company. 

 

	(B)	The Seller is the sole legal and beneficial owner of the Share (as defined below). 

  

	(C)	The Seller has agreed to sell and the Buyer has agreed to buy the Share in consideration for the Consideration Shares and upon the terms set out in this Deed. 

IT IS AGREED as follows: 
  

	1.	INTERPRETATION 

  

	 	1.1	In this Deed, the following expressions have the following meanings: 

  

					
	 	 	“Completion”	  	means completion of the transfer of the Share in exchange for the
Consideration Shares in accordance with Clause 4 of this Deed;
			
		 	“Completion Date”	  	means the date of this Deed;
			
		 	“Consideration Shares”	  	means the 9,166,667 ordinary shares of US$0.001 each in the capital of the Buyer to be issued as fully paid up to the Seller;
			
		 	“Encumbrance”	  	means a mortgage, charge, pledge, lien, option, restriction, third party right or interest, other encumbrance or security interest of any kind or another type of preferential arrangement (including, without limitation, a title
transfer or retention arrangement) or any right to a dividend payment arising on any shares;
			
		 	“Share”	  	means the one fully paid ordinary share of US$1.00 par value in the Company; and
			
		 	“US$”	  	means the U.S. dollar, the lawful currency unit of the United States of America.

  

	 	1.2	In this Deed: 

  

	 	(a)	references to a document in the “agreed form” are to that document in the form agreed to and initialled for the purposes of identification by or on behalf of the parties; 

 

	 	(b)	references to a clause or schedule are to a clause or schedule of this Deed, and references to this Deed include the schedules; 

  

	 	(c)	the headings in this Deed do not affect its construction or interpretation; 

  

	 	(d)	the singular includes the plural and vice versa and any gender includes any other gender; and 

  
 -2- 

	 	(e)	references to writing shall be deemed to include any modes of reproducing words in a legible or non-transitory form. 

  

	2.	AGREEMENT OF THE BUYER TO ISSUE CONSIDERATION SHARES TO THE SELLER 

 Subject to the terms
of this Deed, the Seller agrees to sell the Share and the Buyer agrees to buy the Share free from any Encumbrance and with all rights attaching to the Share as at the date of this Deed, and the Buyer agrees to issue the Consideration Shares directly
to the Seller. 
  

	3.	CONSIDERATION 

 The consideration for the sale of the Share by the Seller to the Buyer
shall be the allotment and issue at Completion to the Seller of the Consideration Shares credited as fully paid in exchange for the Share. 
  

	4.	COMPLETION 

  

	 	4.1	Completion shall take place at the offices of the Seller on the Completion Date. 

  

	 	4.2	On or prior to Completion, the Seller shall procure that the directors of the Company shall hold a board meeting at which the transfer of the Share to the Buyer is approved for registration in the Company’s books
and thereupon a share certificate is issued in favour of the Buyer. 

  

	 	4.3	At Completion the Seller shall deliver or cause to be delivered to the Buyer: 

  

	 	(a)	a duly executed transfer of the Share in favour of the Buyer together with the relevant share certificate (or an indemnity in a form approved by the Buyer in relation to a lost share certificate) in respect of the
Share; and 

  

	 	(b)	a tax reference number of the Seller for the purposes of the Stamp Duty (E-stamping of Instruments) Regulations 2009. 

  

	 	4.4	On or prior to Completion, the Buyer: 

  

	 	(a)	shall procure that a meeting of the board of directors of the Buyer is convened at which the Consideration Shares are allotted; and 

  

	 	(b)	shall deliver to the Seller a share certificate for the Consideration Shares. 

  

	5.	WARRANTIES 

  

	 	5.1	The Seller represents and warrants to the Buyer that: 

  

	 	(a)	the Seller is the sole legal and beneficial owner of the Share; 

  

	 	(b)	the Share has been properly issued and allotted and is fully paid; 

  

	 	(c)	the Share is free from any Encumbrance; 

  

	 	(d)	the Seller has the legal right and full power and authority to execute and deliver, and to exercise its rights and perform its obligations under this Deed; and 

 

	 	(e)	this Deed and all other documents to be executed by the Seller will, when executed, constitute lawful, valid and binding obligations of the Seller in accordance with their respective terms. 

  
 3 

	 	5.2	The Buyer represents and warrants to the Seller that: 

  

	 	(a)	the Consideration Shares will be validly issued and allotted fully paid and free from any Encumbrance and that there is no agreement or commitment outstanding to create an Encumbrance in relation to the Consideration
Shares in favour of any person and no claim has been made by any person with respect to the Consideration Shares; 

  

	 	(b)	the Buyer has the legal right and full power and authority to execute and deliver, and to exercise its rights and perform its obligations under this Deed; and 

 

	 	(c)	this Deed and all other documents to be executed by the Buyer will, when executed, constitute lawful, valid and binding obligations of the Buyer in accordance with their respective terms. 

 

	6.	POWER OF ATTORNEY 

  

	 	6.1	Subject to Completion, the Seller hereby irrevocably and unconditionally appoints the Buyer as its lawful attorney (the “Attorney”) with full power to exercise its rights as a shareholder of the Company
pending stamping and registration of the transfer of the Share and the Seller hereby undertakes to ratify and confirm any action lawfully taken by its Attorney pursuant to this power of attorney and to indemnify its Attorney against all actions,
damages, expenses, costs and claims which may be suffered by or made against its Attorney pursuant to the bona fide exercise by it of this power of attorney. 

 

	 	6.2	As from Completion, the Seller undertakes not to exercise any rights attaching to the Share or exercisable in its capacity as a registered holder thereof without the Buyer’s written consent. 

 

	 	6.3	As from Completion, the Seller undertakes to hold on trust for the Buyer and to promptly notify the Buyer of anything received by it in its capacity as registered holder of the Share and to act promptly in accordance
with the Buyer’s instructions. 

  

	7.	ASSIGNMENT 

 No party shall be entitled to assign or transfer all or any of its rights,
benefits and obligations under this Deed without the prior written consent of the other party. 
  

	8.	VARIATION 

 Any variation of this Deed must be in writing and signed by each party or, in
the case of a body corporate, a duly authorised officer or representative of such party. 
  

	9.	WAIVER 

 A delay in exercising, or failure to exercise, any right or remedy under this
Deed does not constitute a waiver of such right or remedy or other rights or remedies nor shall either operate so as to bar the exercise or enforcement thereof. 
  

	10.	EFFECT OF COMPLETION 

 Except to the extent that they have been performed and except
where the Deed provides otherwise, the warranties, representations, indemnities and obligations contained in this Deed remain in force after Completion. 

  
 4 

	11.	COUNTERPARTS 

 This Deed may be executed in any number of counterparts, each of which
when executed and delivered constitutes an original of this Deed, but all the counterparts shall together constitute one and the same agreement. No counterpart shall be effective until each party has executed at least one counterpart. 

 

	12.	PROPER LAW AND SUBMISSION TO JURISDICTION 

 This Deed shall in all respects be governed
by and construed in accordance with the laws of Ireland and the parties hereto agree to submit to the exclusive jurisdiction of the Irish courts in respect of any claim arising hereunder. 

  
 5 

 SCHEDULE 1 

The Company 
  

					
	1.	    	Name:	  	Presbia Ireland, Limited
			
	2.	    	Type of company:	  	Private limited company
			
	3.	    	Registered Number:	  	532722
			
	4.	    	Date of incorporation:	  	13 September 2013
			
	5.	    	Place of incorporation:	  	Ireland
			
	6.	    	Address of registered office:	  	Arthur Cox Building, Earlsfort Terrace, Dublin 2
			
	7.	    	Authorised share capital:	  	 US$1,000,000 divided into 1,000,000 ordinary shares of

US$1.00 each

			
	8.	    	Issued share capital:	  	1 ordinary share of US$1.00
			
	9.	    	Directors:	  	Gary Kidson and Zohar Loshitzer
			
	10.	    	Secretary:	  	Linda VanDenburgh
			
	11.	    	Assistant Secretary:	  	Bradwell Limited
			
	12.	    	Tax residence:	  	Ireland
			
	13.	    	Charges:	  	Nil
			
	14.	    	Shareholding:	  	

  

					
	Name of Registered Shareholder	 	
Nominal Value and Class of

Share
	 	
Number of

Shares

	Presbia Holdings	 	Ordinary shares of US$1.00 each	 	1

  
 6 

 IN WITNESS WHEREOF THIS DEED WAS EXECUTED BY THE PARTIES HERETO ON THE DATE SET OUT AT THE BEGINNING OF THIS DEED

  

			
	 Executed as a DEED by
 PRESBIA
HOLDINGS
	 	
		 	/s/ Zohar Loshitzer
		 	Zohar Loshitzer, Director
		
		 	/s/ Pamela Tonne
		 	Witness
		 	
	 GIVEN under the common seal of

PRESBIA PLC
 and DELIVERED as a
DEED:
	 	
		 	/s/ Zohar Loshitzer
		 	Zohar Loshitzer, Director
		
		 	/s/ Gary Kidson
		 	Gary Kidson, Director/Secretary

  
 7EX-4.1

 Exhibit 4.1 

NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF THIS WARRANT. 

WARRANT AGREEMENT 
 To Purchase
Shares of Common Stock of 
 BIND THERAPEUTICS, INC. 

Dated as of January 23, 2015 (the “Effective Date”) 

WHEREAS, BIND THERAPEUTICS, INC., a Delaware corporation (the “Company”), has entered into a First Amendment to Amended and
Restated Loan and Security Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology III, L.P., a Delaware limited partnership (the “Warrantholder”); 

WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other things, the financial accommodations provided for in
the Loan Agreement, the right to purchase shares of Common Stock (as defined below) pursuant to this Warrant Agreement (the “Agreement”); 

NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial accommodations
contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE COMMON STOCK. 

For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the
conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to the aggregate number of shares of fully paid and non-assessable shares of the Common Stock (as defined below) as is equal to the quotient derived by dividing
(a) $450,000 by (b) the Exercise Price, at a purchase price per share equal to the Exercise Price. The number of shares and Exercise Price are subject to adjustment as provided in Section 8. As used herein, the following terms shall
have the following meanings: 
 “Act” means the Securities Act of 1933, as amended. 

“Charter” means the Company’s Certificate of Incorporation or other constitutional document, as may be amended and/or
restated from time to time. 
 “Common Stock” means the Company’s common stock, $0.0001 par value per share. 

“Exercise Price” means a price equal to $5.54, as may be adjusted from time to time in accordance with Section 8. 

 “Merger Event” means a merger or consolidation involving the Company in which
the Company is not the surviving entity or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital stock of another entity. 

“Purchase Price” means, with respect to any exercise of this Agreement, an amount equal to the Exercise Price as of the
relevant time multiplied by the number of shares of Common Stock requested to be exercised under this Agreement pursuant to such exercise. 

SECTION 2. TERM OF THE AGREEMENT. 

Except as otherwise provided for herein, the term of this Agreement and the right to purchase Common Stock as granted herein (the
“Warrant”) shall commence on the Effective Date and shall be exercisable until 5:00 p.m., Eastern time, on the fifth anniversary of the Effective Date (the “Expiration Date”). 

SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or
from time to time, prior to the Expiration Date, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and executed.
Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than five (5) business days thereafter, the Company shall issue to the Warrantholder a
certificate for the number of shares of Common Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares
which remain subject to future exercises, if any. 
 The Purchase Price may be paid at the Warrantholder’s election either (i) by
cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder,
as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method of exercise, the Company will issue Common Stock in accordance with the following formula: 

 

			
	X =	  	Y(A-B)
		  	    A

  

					
	Where:	 	X =	  	the number of shares of Common Stock to be issued to the Warrantholder.
			
		 	 Y =
	  	the number of shares of Common Stock requested to be exercised under this Agreement.
			
		 	 A =
	  	the fair market value of one (1) share of Common Stock at the time of issuance of such shares of Common Stock.
			
		 	 B =
	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Common Stock shall mean with respect to
each share of Common Stock: 
 (A) if the Common Stock is traded on a securities exchange, then the fair market value shall
be deemed to be the average of the closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined; or 

  
 2 

 (B) if the Common Stock is traded over-the-counter, then the fair market value
shall be deemed to be the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the Common Stock is
being determined; 
 (C) if at any time the Common Stock is not listed on any securities exchange or quoted in the NASDAQ
National Market or the over-the-counter market, the current fair market value of Common Stock shall be the fair market value of Common Stock as determined in good faith by its Board of Directors, provided that in the event that the exercise is in
connection with a Merger Event, the fair market value of Common Stock shall be deemed to be the per share value received by the holders of the Common Stock pursuant to such Merger Event as determined in good faith by its Board of Directors. 

Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue an amended Agreement representing the remaining number
of shares of Common Stock purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof. 

(b) Exercise Prior to Expiration. To the extent this Agreement is not previously exercised as to all Common Stock subject hereto, and
if the fair market value of one share of the Common Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even if not surrendered) immediately prior to the
Expiration Date. For purposes of such automatic exercise, the fair market value of one share of the Common Stock upon such Expiration Date shall be determined pursuant to Section 3(a). To the extent this Agreement or any portion thereof is
deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Common Stock, if any, the Warrantholder is to receive by reason of such automatic exercise. 

SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of Common Stock to
provide for issuance of the Common Stock hereunder. 
 SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such
fractional shares, the Company shall make a cash payment therefor in an amount equal to the product of (i) the Exercise Price then in effect multiplied by (ii) the fraction of a share. 

SECTION 6. REGISTRATION RIGHTS; NO OTHER RIGHTS AS STOCKHOLDER. 

If the Company proposes to effect a registration of shares of Common Stock under the Act for the public offering of shares of Common Stock by
stockholders solely for cash, the Company shall give the Warrantholder notice of such registration. Upon the request of the Warrantholder given within five (5) days after such notice is given by the Company, the Company shall cause to be
registered the Common Stock issuable upon exercise of this Warrant (the “Warrant Shares”) that the Warrantholder has requested to be included in such registration. 

  
 3 

 
In connection with any public offering involving an underwriting of shares of Common Stock, the Company shall not be required under this Section 6 to include any of the Warrant Shares in
such underwriting unless the Warrantholder accepts the terms of the underwriting as agreed upon between the Company and the underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the
underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. This Section 6 shall terminate and have no further force or effect at such time as Rule 144 promulgated under the Act or another
similar exemption under the Act is available for the sale of all of the Warrant Shares during a three-month period without registration. This Agreement does not entitle the Warrantholder to any voting rights or other rights as a stockholder of the
Company prior to the exercise of the Warrant. 
 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. The Warrantholder’s initial
address, for purposes of such registry, is set forth in Section 12(e) of this Agreement. The Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 

The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment, as follows: 

(a) Merger Event. If at any time there shall be a reorganization, recapitalization, reclassification, consolidation or merger involving
the Company in which the Common Stock is converted into or exchanged for securities, cash or other property or a Merger Event (collectively, a “Reorganization”), then, as a part of such Reorganization, lawful provision shall be made
so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the kind and amount of securities, cash or other property resulting from such Reorganization that would have been issuable if Warrantholder had
exercised this Agreement immediately prior to the Reorganization. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Agreement
with respect to the rights and interests of the Warrantholder after the Reorganization to the end that the provisions of this Agreement (including adjustments of the Exercise Price and number of shares of Common Stock purchasable) shall be
applicable in their entirety and to the greatest extent possible. Without limiting the foregoing, in connection with any Reorganization, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Agreement. In
connection with a Reorganization and upon Warrantholder’s written election to the Company at least ten (10) days prior to the effectiveness of such Reorganization, the Company shall cause this Warrant Agreement to be exchanged for the
consideration that Warrantholder would have received if Warrantholder chose to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement, without actually exercising such right, acquiring such shares,
and exchanging such shares for such consideration. In any such case, appropriate adjustment (as determined in good faith by the Board) shall be made in the application of the provisions set forth herein with respect to the rights and interests
thereafter of the Warrantholder, to the end that the provisions set forth in this Section 8 (including without limitation provisions with respect to changes in and other adjustments of the Exercise Price) shall thereafter be applicable, as
nearly as reasonably may be, in relation to any securities, cash or other property thereafter deliverable upon the exercise of this Warrant. 

(b) Reclassification of Shares. Except as set forth in Section 8(a), if the Company at any time shall, by combination,
reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same 

  
 4 

 
or a different number of securities of the same class or any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would
have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. 

(c) Subdivision or Combination of Shares. If the Company at any time shall subdivide or combine its Common Stock, (i) in the case
of a subdivision, the Exercise Price shall be proportionately decreased, and the number of shares of Common Stock issuable upon exercise of this Agreement shall be proportionately increased, or (ii) in the case of a combination, the Exercise
Price shall be proportionately increased, and the number of shares of Common Stock issuable upon the exercise of this Agreement shall be proportionately decreased. 

(d) Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 

(i) pay a dividend with respect to the Common Stock payable in Common Stock, then the Exercise Price shall be adjusted, from
and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the
numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Common Stock outstanding immediately
after such dividend or distribution; or 
 (ii) make any other distribution with respect to Common Stock, except any
distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate
share of any such distribution as though it were the holder of the Common Stock as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 

(e) Notice of Adjustments. If: (i) the Company shall declare any dividend or distribution upon its Common Stock, whether in stock,
cash, property or other securities; (ii) the Company shall offer for subscription pro rata to the holders of any class of its Common Stock or other stock any additional shares of stock of any class or other rights; (iii) there shall be any
Merger Event; or (iv) the Company shall sell, lease, exclusive license or otherwise transfer all or substantially all of its assets; or (v) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in
connection with each such event, the Company shall send to the Warrantholder: (A) at least ten (10) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend,
distribution, subscription rights (specifying the date on which the holders of Common Stock shall be entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the case of
any such Merger Event, sale, lease, exclusive license or other transfer of all or substantially all assets, dissolution, liquidation or winding up, at least ten (10) days’ prior written notice of the date when the same shall take place
(and specifying the date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding up). 

Each such written notice shall set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is
required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to
purchase hereunder 

  
 5 

 
after giving effect to such adjustment. Such written notice shall be given by first class mail, postage prepaid, by reputable overnight courier with all charges prepaid or via electronic
transmission, addressed to the Warrantholder at the address for Warrantholder set forth in Section 12(f). 
 SECTION 9.
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 
 The Company makes the following representations and warranties to
Warrantholder as of the Effective Date. 
 (a) Reservation of Common Stock. The Common Stock issuable upon exercise of the
Warrantholder’s rights under this Agreement has been duly and validly reserved and, when the Common Stock is issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of
any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Common Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The Company has
made available to the Warrantholder true, correct and complete copies of its Charter and bylaws currently in effect. The issuance of certificates for shares of Common Stock upon exercise of this Agreement shall be made without charge to the
Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Common Stock; provided, that the Company shall not be required to pay any tax
which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 

(b) Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company
hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Charter or
current bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or
other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms except (a) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and (b) as limited by laws relating to the availability of specific performance, injunctive relief, or
other equitable remedies. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking
of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for the filing of
notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. 

(d) [Reserved] 
 (e) Exempt
Transaction. Subject to the accuracy of the Warrantholder’s representations set forth in Section 10, the issuance of the Common Stock upon exercise of this Agreement will each constitute a transaction exempt from (i) the
registration requirements of Section 5 of the Act and (ii) the qualification requirements of the applicable state securities laws. 

(f) Compliance with Rule 144. If the Warrantholder proposes to sell Common Stock issuable upon the exercise of this Agreement, in
compliance with Rule 144 promulgated by the SEC, then, upon the Warrantholder’s written request to the Company, the Company shall furnish 

  
 6 

 
to the Warrantholder, within ten (10) days after receipt of such request, a written statement indicating whether the Company is in compliance with the filing requirements of the SEC as set
forth in such Rule, as such Rule may be amended from time to time. 
 (g) Information Rights. In the event that the Company is no
longer subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, during the term of this Warrant, the Company shall furnish to the Warrantholder quarterly and annual financial statements prepared in accordance with
GAAP, consistently applied, promptly after such financial statements are available, and in any case as to any (i) quarterly financial statements within 45 days after the end of each quarter and (ii) as to annual financial statements within 180 days
after the fiscal year end. 
 SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 

(a) Investment Purpose. This Agreement and the Common Stock issuable upon exercise of the Warrantholder’s rights contained herein
are and will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption. 
 (b) Private Issue. The Warrantholder understands (i) that the Common Stock issuable upon exercise
of this Agreement is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements thereof, and
(ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 
 (c)
Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment.

 (d) Risk of No Registration. The Warrantholder understands that if the Company does not file reports pursuant to
Section 15(d) of the Securities Exchange Act of 1934 (the “1934 Act”) or if a registration statement covering the securities under the Act is not in effect when it desires to sell the rights to purchase Common Stock pursuant to
this Agreement or (ii) the Common Stock issuable upon exercise of the right to purchase, it may be required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to
purchase Common Stock or (B) Common Stock issued or issuable hereunder which might be made by it in reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 

(e) Accredited Investor. Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule 501
of Regulation D, as presently in effect. 
 (f) No Hedging or Short Sales. Warrantholder represents that it has not engaged in, and
covenants and agrees with the Company that it will not engage in, any short sale of Common Stock or hedging activity relating to the Common Stock. 

SECTION 11. TRANSFERS. 

Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole and
not in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when
endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, 

  
 7 

 
shall be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by
this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”) at its
principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all
purposes. 
 SECTION 12. MISCELLANEOUS. 

(a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company and the Warrantholder. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by
suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the non-defaulting party will not have an adequate remedy at
law and where damages will not be readily ascertainable. Each party expressly agrees that it shall not oppose an application by the other party or any other person entitled to the benefit of this Agreement requiring specific performance of any or
all provisions hereof or enjoining a party from continuing to commit any such breach of this Agreement. 
 (c) Additional Documents.
The Company, upon execution of this Agreement, shall provide the Warrantholder with certified resolutions with respect to the representations, warranties and covenants set forth in Sections 9(a) through 9(c). 

(d) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto,
the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(d), attorneys’ fees shall include without limitation fees
incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and
third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 

(e) Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or
unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the
intention of the parties underlying the invalid, illegal or unenforceable provision. 

  
 8 

 (f) Notices. Except as otherwise provided herein, any notice, demand, request, consent,
approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served,
given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile, electronic transmission or hand delivery if such transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the
recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express service or overnight mail delivery service; or
(ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 

If to Warrantholder: 
 Hercules
Technology III, L.P. 
 Legal Department 

Attention: Chief Legal Officer and Manuel Henriquez 

400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 
 Facsimile:
650-473-9194 
 Telephone: 650-289-3060 

Email: jbourque@herculestech.com 

If to the Company: 
 BIND
THERAPEUTICS, INC. 
 325 Vassar Street 

Cambridge, MA 02139 
 Attention:
Chief Financial Officer 
 Facsimile: 617-491-0351 

Telephone: 617-491-3400 x250 

Email: ahirsch@bindtherapeutics.com 

With a copy to: 

Latham & Watkins LLP 

John Hancock Tower, 27th Floor 

200 Clarendon Street 
 Boston,
MA 02116 
 Attention: Peter N. Handrinos 

Facsimile: 617-948-6001 

Telephone: 617-948-6060 
 Email:
peter.handrinos@lw.com 
 or to such other address as each party may designate for itself by like notice, provided that any notice delivered to
Warrantholder or Company shall be valid notwithstanding the failure to deliver a copy of such notice to any other person or entity. 
 (g)
Entire Agreement; Amendments. This Agreement constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets,
letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of the terms of this Agreement may be amended except by a written instrument executed by each of the parties hereto.

 (h) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or
interpretation of this Agreement or any provisions hereof. 
 (i) No Strict Construction. The parties hereto have participated
jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof
shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 

  
 9 

 (j) No Waiver. No omission or delay by Warrantholder at any time to enforce any right or
remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor shall it in any way
affect the right of Warrantholder to enforce such provisions thereafter. 
 (k) Survival. All agreements, representations and
warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement.

 (l) Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of
Delaware, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 (m) Consent to
Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in Santa Clara County, State of California. By execution and
delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, California;
(c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. 

(n) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and
economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws.
EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE
COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY THE WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than the Company and Warrantholder; Claims that arise out
of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement. 

(o) Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of
counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

(p) Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to
Warrantholder or Company by reason of the other’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by Warrantholder and Company, as applicable. If
Warrantholder or Company institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that the instituting entity has an
adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

  
 10 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its officers thereunto duly
authorized as of the Effective Date. 
  

							
	 COMPANY:
	 		 	BIND THERAPEUTICS, INC.
				
		 		 	By:	 	 /s/ Andrew Hirsch

				
		 		 	Title:	 	Chief Operating Officer, Chief Financial Officer and Secretary
			
	 WARRANTHOLDER:
	 		 	HERCULES TECHNOLOGY III, L.P.,
		 		 	a Delaware limited partnership
		 		 	By:	 	 Hercules Technology SBIC Management, LLC,
 its
General Partner

		 		 	By:	 	Hercules Technology Growth Capital, Inc.,
		 		 		 	its Manager
				
		 		 	By:	 	 /s/ Ben Bang

				
		 		 	Title:	 	Associate General Counsel

 EXHIBIT I 

NOTICE OF EXERCISE 
  

	To:	BIND THERAPEUTICS, INC. 

  

	(1)	The undersigned Warrantholder hereby elects to purchase [            ] shares of the Common Stock, pursuant to the terms of the Agreement dated
January 23, 2015 (the “Agreement”) between the Company and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects
pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

  

	(2)	Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below. 

 

	
	  

	
	(Name)
	
	  

	
	(Address)

  

									
	WARRANTHOLDER:	 		 	HERCULES TECHNOLOGY III, L.P.,
		 		 	a Delaware limited partnership
		 		 	By:	 	 Hercules Technology SBIC Management, LLC,

its General Partner

		 		 	By:	 	Hercules Technology Growth Capital, Inc.,
		 		 		 	its Manager
					
		 		 		 	By:	 	  

					
		 		 		 	Title:	 	  

					
		 		 		 	Date:	 	  

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology III, L.P. to purchase [            ] shares of Common Stock of the Company, pursuant to the terms
of the Agreement, and further acknowledges that [            ] shares remain subject to purchase under the terms of the Agreement. 

 

							
	 COMPANY:
	 		 	BIND THERAPEUTICS, INC.
				
		 		 	By:	 	  

				
		 		 	Title:	 	  

				
		 		 	Date:	 	  

  
 13 

 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer or assign the
foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

 
 (Please Print) 

 

			
	whose address is	  	  

  
  

 

			
	Dated:	 	  

 
			
		
	Warrantholder’s Signature:	 	  

		
	Warrantholder’s Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]